【摘要】 目的:比较艾司西酞普兰与舍曲林治疗伴焦虑症状的抑郁症疗效和安全性。方法:76例符合入组标准的患者随机分为艾司西酞普兰组和盐酸舍曲林组各38例,疗程6周。用汉密尔顿抑郁量表(HAMD-17)、汉密尔顿焦虑量表(HAMA)评定疗效,采用治疗中出现的症状量表(TESS)评定安全性。结果:两组HAMD、HAMA评分均较治疗前显著降低(P<0.01),以艾司西酞普兰组HAMD、HAMA评分在治疗1周时降分显著低于盐酸舍曲林组(t=-2.839,-2.862;P<0.01),其余各周差异无统计学意义(P>0.05)。艾司西酞普兰组与舍曲林组不良反应发生率分别为39.5%和42.1%(P>0.05)。结论:艾司西酞普兰与舍曲林治疗伴焦虑症状的抑郁症疗效相当,但艾司西酞普兰起效更快。更多还原

【Abstract】 Objective:To evaluate the efficacy and safety of escitalopram and sertraline in the treatment of depression with anxiety.Method:76 of patients with depression with anxiety were randomly assigned to receive escitalopram(n=38) or sertraline(n=38) for up to 6 weeks in this randomized,parallel-group study.The rapeutic efficacy was assessed with Hamilton depression scale(HAMD-17) and Hamilton anxiety scale(HAMA).Safety profile was assessed with treatment emergent symptom scale(TESS).Results:The mean values of HAMD-17 and HAMA total scores improved significantly for both groups from the baseline to the end of week 6th(P<0.01).At the end of the first week,the total scores of HAMD and HAMA in the group of escitalopram were significant lower than that of group of sertraline(t=-2.839,-2.862;P<0.01),but there were no statistically significant differences between two groups at the end of week 2,4 and 6th(P>0.05).The incidences of side effects were 39.5% in escitalopram group and 42.1% in sertraline group(P>0.05).Conclusion:The therapeutic effect and side effect on depression with anxiety are not different between escitalopram and sertraline.Escitalopram has earlier response than sertraline.更多还原